Blood-based biomarkers for Alzheimer’s disease: Assay development and clinical validation

Elisabeth Hubertina Thijssen

    Research output: PhD ThesisPhD-Thesis - Research and graduation internal

    168 Downloads (Pure)

    Abstract

    In the past five years, major progress has been made in the field of blood-based biomarkers. This thesis shows that the key pathological hallmarks of AD, being amyloid aggregation, tau accumulation, neurodegeneration, and astrocytosis, can be reflected with biomarker measurements in blood. We found that biomarker concentrations vary across different neurodegenerative diseases and are thus valuable for differential diagnosis. We developed and validated an assay to measure the Abeta42/40 ratio in plasma, that reflected amyloid-PET positivity. Plasma P-tau181 and P-tau217 were specifically increased in participants with Alzheimer’s pathology. And NfL and GFAP contributed to biomarker panels for differential diagnosis. In addition, we developed a CSF assay that can detect acetylated tau, important for monitoring of treatment effect of tau acetylation targeting therapies. Nevertheless, there are some challenges ahead on the road to clinical implementation. The optimal panel of biomarkers for different diagnostic questions should be further established and tested in a real-world setting. Then the appropriate steps can be taken to implement blood-based biomarkers in daily clinical practice for diagnosis of AD.
    Original languageEnglish
    QualificationDr.
    Awarding Institution
    • Vrije Universiteit Amsterdam
    Supervisors/Advisors
    • Teunissen, C.E., Supervisor, External person
    • Scheltens, Philip, Supervisor, External person
    • Boxer, Adam, Co-supervisor, External person
    Award date15 Nov 2021
    Publication statusPublished - 15 Nov 2021

    Keywords

    • Blood-based biomarkers
    • Alzheimer's disease
    • neurodegeneration
    • assay development
    • validation

    Fingerprint

    Dive into the research topics of 'Blood-based biomarkers for Alzheimer’s disease: Assay development and clinical validation'. Together they form a unique fingerprint.

    Cite this